The objectives of this study are to: 1) describe the prevalence of neuropathic pain (NP) in breast cancer survivors and 2) to develop preliminary statistical risk models for predicting the risk for NP incorporating disease-related variables (e.g., stage of disease, location of tumor), treatment variables (chemotherapy, dose, duration; and other cancer therapy), clinical health status (e.g., comorbid conditions), and sociodemographic characteristics (e.g., age, sex, race). Researchers will also gather data to answer the following secondary aims: 1. To assess the impact of NP on quality of life. 2. To assess the current management of NP in cancer (current medication, duration of such treatment, reasons for discontinuation) and the outcomes of this management.
No linked publications found in PubMed
Inclusion Criteria: * Breast cancer patients who were participants in clinical trials (ID98-240; ID94-002) for taxanes during 1994-2001 * Alive and with current contact information * Age ≥ 18 years. (This restriction is based on inclusion criteria for the clinical trials from which subjects will be recruited. All patients will be at least 18 years or older for this study.) Exclusion Criteria: 1\) None